143 related articles for article (PubMed ID: 21843081)
1. Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment.
DeRose P; Thorpe PE; Gerber DE
Immunotherapy; 2011 Aug; 3(8):933-44. PubMed ID: 21843081
[TBL] [Abstract][Full Text] [Related]
2. Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors.
Gerber DE; Stopeck AT; Wong L; Rosen LS; Thorpe PE; Shan JS; Ibrahim NK
Clin Cancer Res; 2011 Nov; 17(21):6888-96. PubMed ID: 21989064
[TBL] [Abstract][Full Text] [Related]
3. Radiation-enhanced vascular targeting of human lung cancers in mice with a monoclonal antibody that binds anionic phospholipids.
He J; Luster TA; Thorpe PE
Clin Cancer Res; 2007 Sep; 13(17):5211-8. PubMed ID: 17785577
[TBL] [Abstract][Full Text] [Related]
4. Role of bevacizumab for the treatment of non-small-cell lung cancer.
Ramalingam S; Belani CP
Future Oncol; 2007 Apr; 3(2):131-9. PubMed ID: 17381412
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
Herbst RS; Johnson DH; Mininberg E; Carbone DP; Henderson T; Kim ES; Blumenschein G; Lee JJ; Liu DD; Truong MT; Hong WK; Tran H; Tsao A; Xie D; Ramies DA; Mass R; Seshagiri S; Eberhard DA; Kelley SK; Sandler A
J Clin Oncol; 2005 Apr; 23(11):2544-55. PubMed ID: 15753462
[TBL] [Abstract][Full Text] [Related]
6. Antagonism of platelet-derived growth factor receptor in non small cell lung cancer: rationale and investigations.
Bauman JE; Eaton KD; Martins RG
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4632-6. PubMed ID: 17671155
[TBL] [Abstract][Full Text] [Related]
7. Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer.
Stasi I; Cappuzzo F
Lung Cancer (Auckl); 2014; 5():43-50. PubMed ID: 28210141
[TBL] [Abstract][Full Text] [Related]
8. Antiphosphatidylserine antibody combined with irradiation damages tumor blood vessels and induces tumor immunity in a rat model of glioblastoma.
He J; Yin Y; Luster TA; Watkins L; Thorpe PE
Clin Cancer Res; 2009 Nov; 15(22):6871-80. PubMed ID: 19887482
[TBL] [Abstract][Full Text] [Related]
9. Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways.
Sandler A; Herbst R
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4421s-4425s. PubMed ID: 16857821
[TBL] [Abstract][Full Text] [Related]
10. Effect of yeast-derived beta-glucan in conjunction with bevacizumab for the treatment of human lung adenocarcinoma in subcutaneous and orthotopic xenograft models.
Zhong W; Hansen R; Li B; Cai Y; Salvador C; Moore GD; Yan J
J Immunother; 2009 Sep; 32(7):703-12. PubMed ID: 19561538
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
12. Emerging profile of cetuximab in non-small cell lung cancer.
Ettinger DS
Lung Cancer; 2010 Jun; 68(3):332-7. PubMed ID: 19783064
[TBL] [Abstract][Full Text] [Related]
13. EGFR inhibitors with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer.
Xu Y; Zhang Y; Ma S
Lung Cancer; 2011 Sep; 73(3):249-55. PubMed ID: 21641672
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
Herbst RS; O'Neill VJ; Fehrenbacher L; Belani CP; Bonomi PD; Hart L; Melnyk O; Ramies D; Lin M; Sandler A
J Clin Oncol; 2007 Oct; 25(30):4743-50. PubMed ID: 17909199
[TBL] [Abstract][Full Text] [Related]
15. The evolving role of cetuximab in non-small cell lung cancer.
Lilenbaum RC
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4432s-4435s. PubMed ID: 16857823
[TBL] [Abstract][Full Text] [Related]
16. [Anti-angiogenic factors in thoracic oncology: successes, failures and prospects].
Marco S; Tomasini P; Greillier L; Barlesi F
Rev Mal Respir; 2011 Dec; 28(10):1216-29. PubMed ID: 22152931
[TBL] [Abstract][Full Text] [Related]
17. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.
Maione P; Gridelli C; Troiani T; Ciardiello F
Oncologist; 2006 Mar; 11(3):274-84. PubMed ID: 16549812
[TBL] [Abstract][Full Text] [Related]
18. Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature.
Grossi F; Aita M; Follador A; Defferrari C; Brianti A; Sinaccio G; Belvedere O
Oncologist; 2007 Apr; 12(4):451-64. PubMed ID: 17470688
[TBL] [Abstract][Full Text] [Related]
19. Clinical relevance of monoclonal antibodies in non small cell lung cancer.
Filipits M
J BUON; 2009 Sep; 14 Suppl 1():S147-52. PubMed ID: 19785057
[TBL] [Abstract][Full Text] [Related]
20. Angiogenesis inhibition in the treatment of lung cancer.
Vokes E; Herbst R; Sandler A
Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
